Literature DB >> 11929953

Activation of cancer-specific gene expression by the survivin promoter.

Rudi Bao1, Denise C Connolly, Maureen Murphy, Jeffrey Green, Jillian K Weinstein, Debra A Pisarcik, Thomas C Hamilton.   

Abstract

BACKGROUND: Survivin, a member of the IAP (inhibitor of apoptosis) gene family, appears to be overexpressed in common cancers but not in corresponding normal adult tissues. To investigate whether the survivin promoter controls cancer cell-specific gene expression, we determined whether the survivin gene promoter could regulate reporter gene expression in cancer cell lines and xenografts.
METHODS: Survivin protein levels were determined in human and murine cancer cell lines and in normal tissues of adult C57BL/6 mice by Western blot analysis. A reporter construct in which a portion of the survivin gene promoter was used to drive transcription of a human secreted alkaline phosphatase (SEAP) gene was transiently transfected into cancer cells, and promoter activity was extrapolated from SEAP activity. A2780 human ovarian cancer cells were transfected with this construct, and stable transfectants were injected into the intrabursal ovarian space of immunodeficient mice. Tumor growth was monitored, and plasma SEAP levels were used as a measure of survivin promoter activity in vivo.
RESULTS: Survivin protein was detected in all cancer cell lines examined but not in most normal adult mouse tissues. After transfection, the survivin promoter was more active in all cancer cell lines than in normal ovarian surface epithelial cells or mouse 3T3 cells. After 0.8 x 10(6) stable transfectant cells were injected into the intrabursal cavity of mouse ovaries, plasma SEAP activity was detected within 24 hours, and the activity increased with time and tumor growth.
CONCLUSION: Transfection experiments indicate that survivin protein expression in cancer tissue appears to be regulated, at least in part, transcriptionally. Thus, the survivin promoter may be useful in controlling gene expression in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11929953     DOI: 10.1093/jnci/94.7.522

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  40 in total

1.  The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin.

Authors:  Anjaiah Srirangam; Monica Milani; Ranjana Mitra; Zhijun Guo; Mariangellys Rodriguez; Hitesh Kathuria; Seiji Fukuda; Anthony Rizzardi; Stephen Schmechel; David G Skalnik; Louis M Pelus; David A Potter
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

2.  Secreted luciferase for in vivo evaluation of systemic protein delivery in mice.

Authors:  Salim S El-Amouri; Phuong Cao; Carol Miao; Dao Pan
Journal:  Mol Biotechnol       Date:  2013-01       Impact factor: 2.695

3.  Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo.

Authors:  Bakhos A Tannous
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

4.  Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.

Authors:  Limin Hu; Judith Hofmann; Charles Zaloudek; Napoleone Ferrara; Thomas Hamilton; Robert B Jaffe
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

5.  The role of survivin in diagnosis, prognosis and treatment of breast cancer.

Authors:  Yong-Gang Lv; Fang Yu; Qing Yao; Jiang-Hao Chen; Ling Wang
Journal:  J Thorac Dis       Date:  2010-06       Impact factor: 2.895

6.  Targeting and eradicating hepatic cancer cells with a cancer-specific vector carrying the Buforin II gene.

Authors:  Yanyun Wang; Lili Qu; Lailing Gong; Li Sun; Rujun Gong; Jin Si
Journal:  Cancer Biother Radiopharm       Date:  2013-06-25       Impact factor: 3.099

7.  Combination Nanopreparations of a Novel Proapoptotic Drug - NCL-240, TRAIL and siRNA.

Authors:  Robert Riehle; Bhushan Pattni; Aditi Jhaveri; Abhijit Kulkarni; Ganesh Thakur; Alexei Degterev; Vladimir Torchilin
Journal:  Pharm Res       Date:  2016-03-07       Impact factor: 4.200

8.  Targeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoter.

Authors:  R Huang; Z Zhao; X Ma; S Li; R Gong; A Kuang
Journal:  Cancer Gene Ther       Date:  2010-10-29       Impact factor: 5.987

9.  hTERT and BIRC5 gene promoters for cancer gene therapy: A comparative study.

Authors:  Mikhail V Shepelev; Eugene P Kopantzev; Tatiana V Vinogradova; Eugene D Sverdlov; Igor V Korobko
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

10.  Tumor-specific gene expression using the survivin promoter is further increased by hypoxia.

Authors:  L Yang; Z Cao; F Li; D E Post; E G Van Meir; H Zhong; W C Wood
Journal:  Gene Ther       Date:  2004-08       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.